Randy Erspamer

Randy Erspamer is Head of Business Development at Intus Biosciences, where he leads commercial strategy for GutID, the company's proprietary long-read sequencing assay for the gut microbiome.

He brings more than a decade of experience in molecular diagnostics and precision health, with previous roles in business development at Abbott and Opgen. Across those roles he built a reputation for straightforward communication and a focus on outcomes over sales pressure.

His current work centers on translating complex science into tools clinicians and consumers can use with confidence, supporting the Intus team's mission to make the microbiome a routine, actionable part of healthcare.